EL7.AI
StocksHigh ImpactUpdated•Originally published 3 March 2026•Updated 3 March 2026•
1 min read

Moderna Seeks to Limit Liability in $2.25 Billion Patent Settlement Appeal

Key Facts

1Moderna will pay $950 million upfront, with an additional $1.3 billion contingent upon the outcome of a court appeal.
2The settlement concerns the unauthorized use of lipid nanoparticle (LNP) delivery technology in COVID-19 vaccines.
3Roivant (Genevant's parent) approved a $1 billion share repurchase program following the settlement.
4This settlement would be the largest of its kind in the pharmaceutical industry if the full amount is realized.

Moderna has reached a global settlement agreement worth up to $2.25 billion with Genevant Sciences and Arbutus Biopharma over LNP technology patents used in mRNA vaccines. The deal involves a $950 million upfront payment, with an additional $1.3 billion contingent on the outcome of further legal proceedings. In a strategic move, Moderna now plans to appeal to a federal circuit court, arguing that its liability is limited due to its status as a government contractor. Following the settlement news, Roivant Sciences, the parent company of Genevant, authorized a $1 billion share repurchase program. This appeal represents Moderna's effort to mitigate the financial impact of the long-standing dispute over its vaccine technology. The case remains a landmark in pharmaceutical intellectual property litigation, providing the company with a framework for long-term legal resolution.